Cell Therapy Beyond CAR-T: CAR-NK, TIL, and the $400M Market

CAR-T gets all the attention. Six approved products, north of $4 billion in annual revenue, a mature commercial market. The CAR-T stocks are covered separately. But CAR-T is just one modality in the cell therapy sector, and the biggest problems with CAR-T are the reason the next wave exists. Manufacturing takes weeks. The therapy works in blood cancers but not solid tumors. A single dose costs $400,000 or more. The next wave of cell therapy, CAR-NK, TIL, and regenerative approaches, is built directly on those three shortcomings. Together, these three non-CAR-T modalities generated under $400 million in revenue last year. CAR-T was a $400 million market in 2020. The argument is that the shape of the next decade is already visible.

CAR-NK: Off-the-Shelf, No CRS, No Manufacturing Wait

Natural killer (NK) cells are the innate immune system’s first line of defense. Unlike T-cells, they do not require HLA matching, which means donor-derived NK cells can be infused into any patient without triggering graft-versus-host disease. That single biological difference is what makes CAR-NK an off-the-shelf product, the same allogeneic advantage that the next-generation CAR-T programs are chasing; you manufacture a bank of engineered NK cells, freeze them, and ship them to the treatment center. No 22-day vein-to-vein wait like TIL. No patient-specific manufacturing like autologous CAR-T.

The CAR-NK field has two notable public companies at very different stages, and the distinction between them is the analytical point.

Nkarta (NKTX) is the pure CAR-NK play. Its lead program, NKX019, targets CD19 and is in Phase 1 trials for lupus nephritis (Ntrust-1, NCT06557265) and a basket of autoimmune diseases (Ntrust-2). The autoimmune pivot matters because it sidesteps the oncology competition with CAR-T. In lupus, the target is pathogenic B-cells, the same CD19 target CAR-T hits in blood cancers, but the commercial argument is different: an off-the-shelf, outpatient therapy that depletes autoreactive B-cells without the CRS and neurotoxicity risk of CAR-T. Nkarta ended Q1 2026 with $266.7 million in cash, enough to fund operations into 2029. At $2.46 per share and a $176 million market cap, the market is pricing NKX019 at near-zero. The catalyst: Ntrust-1 lupus nephritis data expected by the end of 2026. If the data shows durable B-cell depletion with a clean safety profile in the first 10 to 15 patients, the stock re-rates toward $500 million to $1 billion on the autoimmune cell therapy thesis alone.

Fate Therapeutics (FATE) is often grouped with CAR-NK, but the distinction is important. Fate’s lead program, FT819, is an iPSC-derived CAR-T cell therapy, not CAR-NK. FT522 is the CAR-NK program. FT819 uses a clonal master iPSC bank as the starting material to manufacture off-the-shelf CD19 CAR-T cells, and the autoimmune pivot is further along here than at Nkarta. RECLAIM-LN, a Phase 2 registrational trial in refractory lupus nephritis with complete renal response at six months as the primary endpoint, is expected to start enrolling in the second half of 2026. Fate presented data at ASGCT 2026 showing FT819 without conditioning chemotherapy achieved SRI-4 responses in 3 of 3 SLE patients at the lowest dose level, a result that makes the outpatient administration thesis concrete. Fate ended Q1 2026 with $174.8 million and runway into 2028. At $2.76 and a $322 million market cap, the RECLAIM-LN initiation is the near-term catalyst.

The CAR-NK thesis has one structural problem: no product has been approved. The entire space is Phase 1 and Phase 2. That makes every catalyst a binary event on a pre-revenue stock. The upside is that NKTX’s $176 million market cap is 0.6 times its cash balance; the market is paying you to take the pipeline risk for free.

TIL Therapy: Amtagvi Is Already Approved

Tumor-infiltrating lymphocyte (TIL) therapy is the one non-CAR-T cell therapy with an FDA approval, and that gives Iovance Biotherapeutics (IOVA) the sector’s only approved product with a commercial ramp to track. Amtagvi (lifileucel) was approved in February 2024 for advanced melanoma after anti-PD-1 therapy, making it the first cell therapy approved for a solid tumor. The commercial ramp is why the stock matters now.

Iovance posted Q2 2026 revenue of $99.3 million, 66% year-over-year growth, with Amtagvi contributing roughly $91 million, as covered in the Iovance Amtagvi Q2 revenue analysis. Gross margin hit 56%, up from 34% a year ago. The company guided $350 million to $370 million for the full year, implying the second-half run rate hits roughly $130 million per quarter. At $6.40 and a $2.9 billion market cap, IOVA trades at roughly 8 times full-year guided revenue, expensive for a single-product biotech but in line with where CAR-T leaders traded at the same point in their commercial ramps.

The bull case is that Amtagvi is under 5% penetrated in an addressable melanoma market of 10,000 to 12,000 US patients per year, and the label expansion pipeline could triple the patient population. A non-small cell lung cancer (NSCLC) BLA is planned, and TILVANCE-301, a Phase 3 trial in frontline melanoma combining lifileucel with pembrolizumab, is enrolling. The bear case is the 22-day manufacturing time, which is even longer than autologous CAR-T. A next-generation process targeting under 16 days is in development, but until it is validated, the logistics cap the growth curve.

Iovance ended Q2 with $303.7 million in cash and a net loss of $47.3 million, or $0.11 per share. The burn rate is manageable at current revenue growth rates, but the company is not yet cash-flow positive. The ESMO melanoma data update in September and the NSCLC filing are the nearest catalysts.

Regenerative Cell Therapy: ReNu and the OA Bet

Organogenesis (ORGO) is the odd one out. It is not an oncology company. ReNu, its cryopreserved amniotic suspension allograft for knee osteoarthritis, is not engineered to kill cancer cells. It is designed to reduce pain and inflammation by delivering growth factors, extracellular matrix components, and amniotic cells into the osteoarthritic joint. The PDUFA date is April 24, 2027, and the regulatory picture is mixed.

The first Phase 3 trial met its primary endpoint: a statistically significant reduction in WOMAC pain score at six months favoring ReNu over saline (-6.0 vs -5.3, p=0.0177). The second Phase 3 trial did not achieve statistical significance for the primary endpoint despite a numerical improvement in baseline pain reduction over the first trial (-6.9). The company filed the BLA based on the totality of the data, and the FDA accepted it. The RMAT designation signals the FDA is willing to consider the full evidence package rather than requiring both trials to hit statistical significance independently.

At $1.86 and a $239 million market cap, ORGO is not a biotech in the traditional sense; it is a regenerative medicine company with an existing commercial wound care business generating revenue. ReNu is the upside option. The downside is that if the FDA issues a complete response letter citing the failed second Phase 3, the stock trades back toward cash value. The risk-reward is binary with a 9-month wait.

The Manufacturing Problem That Decides the Winner

Every autologous cell therapy requires vein-to-vein logistics: harvest cells from the patient, manufacture the therapy, ship it back, infuse. CAR-T manufacturing takes 2 to 4 weeks. TIL takes 22 days. CAR-NK solves this by being allogeneic; you manufacture a bank once and dose any patient immediately. Regenerative cell therapy sits somewhere in between; ReNu is an allograft from donor tissue, not patient-specific, but it still requires tissue processing and cryopreservation.

The manufacturing scalability question is the analytical framework for ranking these modalities. The modality with the shortest vein-to-vein time and lowest cost per dose will capture the most patients. CAR-NK has the theoretical edge; TIL has the commercial proof. The tension between those two statements is the entire investment thesis for the next decade of cell therapy.

No CAR-NK product is approved. TIL has one approval and $99 million in quarterly revenue. But the first company to get a CAR-NK product across the FDA finish line, most likely in autoimmune disease where the safety bar is higher and the off-the-shelf convenience is the differentiator, resets the entire sector’s valuation.

Investment Framework

The three modalities map to three investor profiles. TIL therapy via Iovance is the only revenue-generating, FDA-approved option. It belongs in the portfolio of investors who want cell therapy exposure without pre-revenue binary risk, but it still comes with a 22-day manufacturing bottleneck and single-product concentration. CAR-NK via Nkarta and Fate is the pre-revenue speculation. The stocks trade below or near cash value. The upside is a 3-to-5x re-rating on positive Phase 1 or Phase 2 data. The downside is a 50% drawdown on a failed trial, mitigated by the cash cushion. Regenerative cell therapy via Organogenesis is a medtech bet in a biotech wrapper; the commercial wound care business provides a floor, and ReNu is the upside call option with a 9-month catalyst timeline.

For a biotech portfolio weighted toward oncology, adding IOVA provides cell therapy exposure with commercial revenue and a roadmap to NSCLC label expansion. For investors willing to take binary risk on a platform that could define the next decade, NKTX at 0.6 times cash with an end-of-2026 data catalyst is the highest risk-reward entry. FATE at $322 million with a Phase 2 registrational trial starting is the middle ground; the market is pricing the iPSC platform at roughly $150 million above cash, which is cheap compared to what the same platform was worth in 2021 but expensive compared to Nkarta’s valuation.

Risks

The structural risk is that no CAR-NK product has ever been approved, and the history of cell therapy is littered with modalities that worked in Phase 1 and failed in Phase 2. Nkarta’s predecessor NKX101 data in AML was modest, and oncology CAR-NK has not yet produced a home-run dataset. The autoimmune pivot is a newer thesis with less clinical validation. For Iovance, the risk is that the 22-day manufacturing time caps the commercial ramp at a level below what the $2.9 billion market cap implies; if NSCLC data disappoints or the next-gen manufacturing process fails, the growth thesis breaks. For Organogenesis, the second failed Phase 3 is a real regulatory risk that the FDA may consider disqualifying despite RMAT designation.

Verdict

Own IOVA for cell therapy commercial exposure with a catalyst-rich second half of 2026; the ESMO data and NSCLC filing are the events that compress or expand the multiple. Take a 1% to 2% position in NKTX ahead of end-of-2026 lupus nephritis data; the asymmetric upside of a 3-to-5x re-rating on positive CAR-NK data is worth the binary risk at a sub-$200 million market cap. Hold FATE into the RECLAIM-LN initiation; the iPSC platform is real but the autoimmune thesis needs a registrational trial to convert the narrative into a valuation. Skip ORGO until the April 2027 PDUFA; the mixed Phase 3 data means the binary risk is effectively a coin flip with a 9-month holding period.

The cell therapy story beyond CAR-T is still in its first act. The $400 million revenue base today is what CAR-T was in 2020. The companies that solve the manufacturing problem, autologous or allogeneic, will be the ones trading at $5 billion-plus five years from now. The bet is that Nkarta’s end-of-2026 data and Iovance’s commercial ramp are the two clearest signals in that story.